Drug Safety
Long-Term Melatonin Use Linked to Increased Heart Failure Risk in Insomnia Patients, Study Finds
A preliminary study suggests adults with insomnia who used melatonin supplements for at least one year had significantly higher rates of heart failure diagnosis, hospitalization and death compared to non-users, raising important safety concerns about the widely available sleep aid.
Nutriband Files Provisional Patent to Strengthen AVERSA Abuse-Deterrent Technology Protection
Nutriband Inc. has filed a provisional patent application to expand protection for its AVERSA abuse-deterrent transdermal technology, potentially extending patent coverage by 20 years and strengthening the company's position in addressing prescription drug misuse.
Nutriband to Present AVERSA Technology Strategy at MicroCap Rodeo Conference
Nutriband Inc.'s upcoming presentation at the MicroCap Rodeo Conference highlights the company's strategic direction for its innovative AVERSA abuse-deterrent technology platform, which addresses critical safety concerns in transdermal pharmaceutical delivery.
7-HOPE Alliance Defends Legality and Safety of 7-OH, Challenges Kratom Association Claims
The 7-HOPE Alliance asserts that 7-hydroxymitragynine is lawful and scientifically supported, countering claims by kratom associations while highlighting potential medical benefits and harm reduction value.
Nutriband Inc. Secures U.S. Patent for AVERSA(TM) Technology, Aiming to Curb Drug Abuse
Nutriband Inc.'s new U.S. patent for its AVERSA(TM) technology marks a significant step forward in preventing the misuse and abuse of transdermal drugs, addressing a critical aspect of the ongoing opioid crisis.
Nutriband Inc. Secures U.S. Patent for Innovative Abuse-Deterrent Transdermal Technology
Nutriband Inc. has been granted a U.S. patent for its Aversa(TM) technology, marking a significant step forward in the fight against drug abuse and misuse with its abuse-deterrent transdermal products.